These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Targeting the Vascular Endothelial Growth Factor Pathway in Gastric Cancer: A Hit or a Miss? Ilson DH J Clin Oncol; 2016 May; 34(13):1431-2. PubMed ID: 26884571 [No Abstract] [Full Text] [Related]
7. Update on HER1-3 in advanced non-small-cell lung cancer. Horn L; Lovly C J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S369-71. PubMed ID: 23160321 [No Abstract] [Full Text] [Related]
8. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046 [TBL] [Abstract][Full Text] [Related]
9. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Wagner AD; Moehler M Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098 [TBL] [Abstract][Full Text] [Related]
10. Innovative personalized medicine in gastric cancer: time to move forward. Lee J; Kim KM; Kang WK; Ou SH Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947 [TBL] [Abstract][Full Text] [Related]
12. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628 [TBL] [Abstract][Full Text] [Related]
13. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. Dalmases A; Rojo F; Rovira A; Albanell J Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407 [No Abstract] [Full Text] [Related]
14. New advances in targeted gastric cancer treatment. Lazăr DC; Tăban S; Cornianu M; Faur A; Goldiş A World J Gastroenterol; 2016 Aug; 22(30):6776-99. PubMed ID: 27570417 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Motoyama AB; Hynes NE; Lane HA Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928 [TBL] [Abstract][Full Text] [Related]
16. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575 [TBL] [Abstract][Full Text] [Related]
18. Phase I and II clinical trials for gastric cancer. Khushalani NI Surg Oncol Clin N Am; 2012 Jan; 21(1):113-28. PubMed ID: 22098835 [TBL] [Abstract][Full Text] [Related]
19. Modern oncological approaches to gastric adenocarcinoma. Wadhwa R; Taketa T; Sudo K; Blum MA; Ajani JA Gastroenterol Clin North Am; 2013 Jun; 42(2):359-69. PubMed ID: 23639645 [TBL] [Abstract][Full Text] [Related]